C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories
27 Junio 2024 - 9:00AM
Business Wire
Healthcare Providers Have Expanded Access to
C2N’s Blood Tests to Better Identify Alzheimer’s Disease
Pathology
C2N Diagnostics, LLC (“C2N”), which provides exceptional
clinical laboratory services and advanced diagnostic solutions in
the field of brain health, has entered into a non-exclusive
agreement with Mayo Clinic Laboratories, for inclusion of C2N’s
Precivity tests in Mayo Clinic Laboratories’ test offerings to its
clients.
The Precivity tests are innovative blood tests intended for use
in patients 55 and older with signs or symptoms of mild cognitive
impairment or dementia. These tests aid healthcare providers in the
detection of amyloid plaques in the brain, a hallmark of
Alzheimer's disease, and help inform medical management and
treatment decisions.
William G. Morice II, M.D., Ph.D., President & CEO, Mayo
Clinic Laboratories says, “By offering C2N’s tests to our clients,
they have access to a portfolio of Alzheimer’s disease tests to
ensure their patients receive the right answers when they need them
most.”
Dr. Joel Braunstein, C2N’s CEO, says, “While C2N Diagnostics
continues expanding its own commercial, operational and IT
infrastructure in the U.S. and strategic countries, we’re extremely
pleased to work with Mayo Clinic Laboratories to broaden access to
Precivity testing through Mayo Clinic Laboratories’ global
distribution channels, extensive U.S. infrastructure and EMR
connectivity. This non-exclusive partnership with Mayo Clinic
Laboratories builds on our exclusive partnerships in other select
markets. Overall, it demonstrates our commitment to excellence in
clinical care and to collaborating with premium diagnostics leaders
to make high-performance Alzheimer’s disease tests more accessible
to healthcare providers and patients around the world. We look
forward to elevating the quality of care for many patients in
clinical need.”
The Precivity tests are only available through a healthcare
provider’s order. The PrecivityAD2™ and PrecivityAD® blood tests
use highly sensitive and specialized laboratory technologies to
identify and measure certain proteins that are found in the blood
and that are known to be associated with presence of brain amyloid
plaques.
The main test result is a multiple analyte-derived algorithm
score that determines a patient’s likelihood category for the
presence of brain amyloid plaques. Like other high-performance
tests that evaluate for brain amyloid pathology in clinical
patients (such as amyloid PET scan or cerebrospinal fluid testing),
the Precivity blood tests by themselves do not diagnose Alzheimer’s
disease. Healthcare providers interpret the test results along with
other medical information.
All of C2N’s Precivity tests are performed under the ISO
13485:2016 standard and in the company’s CAP accredited, CLIA
certified laboratory.
About C2N Diagnostics, LLC
C2N is a specialty diagnostics company with a vision to bring
Clarity Through Innovation®. C2N strives to provide exceptional
clinical laboratory services and advanced diagnostic solutions in
the field of brain health. C2N’s high-resolution mass
spectrometry-based biomarker services and products are used for:
clinical decision-making to improve patient care, including
diagnosis and treatment monitoring; maximizing the quality and
efficiency of clinical trials that test novel treatments for
neurodegeneration; and providing innovative tools to help
healthcare researchers better understand novel mechanisms of
disease, identify new treatment targets, and conduct important
epidemiologic studies to improve global public health. C2N assays
have been used in over 150 Alzheimer’s disease and other research
studies throughout the U.S. and the world. This includes landmark
treatment and prevention trials involving disease-modifying
therapies (DMTs) that are changing the trajectory of Alzheimer’s
disease. C2N has ongoing collaborations with multi-national
pharmaceutical and biotech companies, leading academic
institutions, National Institute on Aging, Alzheimer’s Association,
and other non-profits and consortiums. Over 30,000
Precivity™-related biomarker measures have been reported through
peer-reviewed publications, with many more manuscripts currently
under review.
The company acknowledges generous support from National
Institute on Aging, GHR Foundation, Alzheimer’s Drug Discovery
Foundation, BrightFocus Foundation and Alzheimer’s Association. For
more information visit www.C2N.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627306505/en/
COMPANY CONTACT: Joni Henderson JHenderson@c2n.com
314-464-0009
MEDIA CONTACT: Adam Shapiro Adam.Shapiro@ASPR.bz
202-427-3603